Casey Woodring
JPMorgan Chase & Co, Research Division
All right. Great. Thank you, everybody, for joining us today. I’m Casey Woodring from the Life Science Tools and Diagnostics team here at JPMorgan. Welcome to our conference. Pleasure to be joined today by the management team of Revvity. I’ll pass it off to CEO, Prahlad Singh, for some prepared remarks and go through the presentation, then we’ll do Q&A afterwards. So Prahlad, how about it?
Prahlad Singh
CEO, President & Director
Thank you, Casey. Good morning. Welcome. We are excited to share with you our story and the progress that we’ve made over the past 12 months since you heard the conference last.
Before I begin, I wanted to invite your attention to our safe harbor statement and encourage you to visit the Investors section on our website, revvity.com, for additional financial disclosures and the latest SEC filings.
All the figures and financials that you’ll hear today are all estimated future results and growth rates presented and what we’ll talk about today are based from our 3Q earnings call guidance that was provided as of October 27, 2025.
For those of you who have been part of our portfolio transformation journey and have followed us will recall, we, a few years ago, we started primarily as an industrial company that was around 1/3 analytical and 1/3 of the business was in primarily small molecule preclinical life sciences and 1/3 of it in diagnostics, which was essentially a mother and child company at that point of time.
Since
